Bioidentical Hormones vs. Traditional HRT: The Honest Answer
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 19 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
Bioidentical hormones vs. traditional HRT: FDA-approved estradiol is bioidentical. Compounded BHRT is not the same. The honest answer, by the evidence.
Hormone therapy for menopause is rife with confusion, fear, misunderstanding, and outright misinformation. Even doctors — who are often relying on long-debunked research — can be at a loss to help women make educated choices for their health and well-being.
If you’ve been researching bioidentical hormones versus traditional HRT, you’ve probably noticed how confusing the conversation is. One side of the internet says bioidenticals are safer, more natural, and tailored to your individual hormone profile. The other side says it’s a marketing term used to sell unregulated, compounded products. Both positions contain partial truths, and the actual answer matters — because the choice you make affects what’s in the medication, how rigorously it’s been studied, and how much you’re protected by FDA oversight.
This guide unpacks what “bioidentical” actually means, separates FDA-approved body-identical hormones (well-studied, mainstream, regulated) from compounded bioidentical hormone therapy (CBHT) (marketed heavily, not supported by guidelines, regulated less), and explains what the major menopause societies have actually said. The honest version is more nuanced than either side of the marketing wars suggests.
Key takeaways
“Bioidentical” is primarily a marketing term, not a clinical category. What matters is whether the specific hormones used are molecularly identical to the ones your body makes, and whether the formulation is FDA-approved.
FDA-approved estradiol and micronized progesterone are bioidentical in molecular structure and are the standard of care in modern menopause medicine. They are well-studied, regulated, and covered by insurance.
Compounded bioidentical hormone therapy (CBHT) — custom-mixed formulations from compounding pharmacies, often based on saliva tests — is not supported by The Menopause Society, ACOG, the Endocrine Society, or the FDA.
The Menopause Society 2022 Hormone Therapy Position Statement explicitly recommends against the use of custom-compounded bioidentical hormones when an FDA-approved alternative exists.
The choice is rarely between “bioidentical and traditional.” It’s between FDA-approved body-identical hormone therapy and unregulated compounded products marketed under the same word.
The short answer
When most patients ask about “bioidentical hormones,” they’re thinking about something they read online — typically a description of custom-compounded creams, pellets, or lozenges sold as a safer, more natural alternative to “traditional HRT.” That framing collapses two very different products under one marketing umbrella.
FDA-approved estradiol (the same molecule your ovaries used to make) and FDA-approved micronized progesterone (the same molecule your corpus luteum used to make) are bioidentical in the strict molecular sense. They’ve been the standard of care in mainstream menopause medicine for two decades. They’re available as pills, patches, gels, rings, and vaginal preparations. They’re FDA-regulated, dose-standardized, covered by insurance, and well-studied.
Compounded bioidentical hormone therapy (CBHT) — typically marketed as “BHRT” — is a different product. These are custom-mixed by compounding pharmacies, often in proprietary combinations, frequently based on saliva hormone testing, and frequently dispensed as pellets implanted under the skin. They are not FDA-approved. They lack standardized dosing, have no large randomized trials supporting their safety or efficacy beyond what’s already known for FDA-approved hormones, and have been the subject of explicit warnings from every major menopause society and from the FDA itself.
The practical answer for most women: FDA-approved bioidentical hormone therapy (estradiol + micronized progesterone) gives you the molecular identity you’ve been told to look for, with all the rigor and safety of regulated medicine. Compounded products do not.
What “bioidentical” actually means
The word “bioidentical” describes molecular structure: a hormone that is chemically identical to one your body produces. 17-beta estradiol is the main estrogen made by your ovaries during reproductive years. Progesterone (specifically, the form labeled “micronized progesterone” to indicate how it’s been processed for oral absorption) is the progestogen made by your corpus luteum. Estriol and estrone are also bioidentical estrogens, though they’re weaker than estradiol.
If a medication contains estradiol, it is bioidentical, period — regardless of whether it came from a compounding pharmacy or from a major pharmaceutical manufacturer. The same is true for micronized progesterone. The molecule is the molecule.
What “bioidentical” does not describe is the formulation, the source, the regulatory status, or anything about how the product was made. A patch of FDA-approved estradiol manufactured to pharmaceutical standards and a compounded estradiol cream from a local pharmacy both contain bioidentical estradiol. They differ on every other dimension that affects safety and efficacy.
By contrast, conjugated equine estrogens (CEE) — the active ingredient in Premarin, derived from pregnant mare urine — is not strictly bioidentical because it’s a mixture of estrogen compounds, some of which differ in structure from human estradiol. CEE has been around since 1942 and was the estrogen used in much of the original Women’s Health Initiative cohort, which is part of why “traditional HRT” sometimes implies CEE specifically. Medroxyprogesterone acetate (MPA), the synthetic progestin in Provera and Prempro, is also not bioidentical — it’s a chemically modified progestin with different effects on tissue than natural progesterone.
This distinction matters for one specific reason: some of the cardiovascular and breast cancer signals in the WHI estrogen-plus-progestin arm were associated with MPA, not progesterone. Newer research, including reanalysis of WHI data and head-to-head comparisons in the E3N French cohort, suggests that micronized progesterone may have a more favorable breast-cancer risk profile than MPA. For more on the long-term safety data, see our pillar on is HRT safe.
FDA-approved body-identical hormone therapy
HRT is a treatment that is safe, very similar to your body's hormones, and doctor-recommended. There shouldn't be so much stigma around hormone therapy because the benefits outweigh the risks.
The medications most modern menopause clinicians prescribe — and the ones supported by The Menopause Society 2022 Hormone Therapy Position Statement, NICE Guideline NG23 (updated November 2024), and the International Menopause Society — are FDA-approved bioidentical preparations.
For estrogen, the FDA-approved bioidentical options include:
Transdermal estradiol patches (multiple brand names and generics, applied once or twice weekly)
Transdermal estradiol gel (applied daily to the skin)
Transdermal estradiol spray (applied daily to the forearm)
Oral estradiol tablets (taken daily)
A manufacturer can legally advertise a supplement 'helps maintain hormone health' or provides 'ovary support' without defining those terms or providing evidence of, well, anything. These quasi-scientific terms are very effective marketing. Who doesn't want to support their ovaries?
Vaginal estradiol (for genitourinary symptoms — rings, tablets, creams)
For progestogen, the FDA-approved bioidentical option is:
Oral micronized progesterone (Prometrium and generics, taken at bedtime)
Vaginal micronized progesterone (off-label for endometrial protection in some clinical settings)
These products are manufactured under FDA Good Manufacturing Practice standards. The dosing is standardized — a 100 mg progesterone capsule contains 100 mg of progesterone. The packaging carries FDA-approved labeling, including pregnancy categories, contraindications, and safety warnings. They’ve been studied in large randomized trials. They’re covered by most insurance.
For women whose clinical situation allows hormone therapy (no contraindications such as estrogen-sensitive cancer history, active venous thromboembolism, active liver disease, or unexplained vaginal bleeding), a standard modern regimen is transdermal estradiol plus oral micronized progesterone. Both are bioidentical. Both are FDA-approved. This is what most contemporary menopause clinicians mean when they say “HRT” or “MHT” (menopausal hormone therapy).
What compounded bioidentical hormone therapy actually is
Compounded bioidentical hormone therapy (CBHT) — often marketed as “BHRT” — refers to custom-mixed hormone preparations made by compounding pharmacies. The compounding pharmacy is given a prescription specifying combinations and doses, often based on a clinician’s interpretation of saliva or serum hormone tests, and prepares a tailored product. Common forms include:
Pellets implanted under the skin (typically every 3-4 months)
Creams applied to the skin
Lozenges or troches dissolved under the tongue
Capsules containing combinations of estrogens, progesterone, testosterone, DHEA, and sometimes thyroid hormone
CBHT is typically marketed as “natural,” “tailored to your individual hormone levels,” “safer than synthetic,” and a “more personalized” approach than FDA-approved products. The marketing emphasizes the molecular bioidentity of the hormones used while obscuring the regulatory and evidence gap.
The reality is more complicated. Compounding pharmacies are regulated by state boards of pharmacy and the FDA’s compounding oversight, but compounded products themselves are not FDA-approved. They have not undergone the manufacturing, dosing, safety, or efficacy review that FDA-approved products have. Lot-to-lot consistency varies. Pellet implantation can produce supratherapeutic hormone levels that are difficult to reverse if side effects occur (you can’t take a pellet out the way you can stop a pill). And many CBHT regimens include components — like routine testosterone or DHEA dosing in women — that don’t have a clear evidence base for the indications they’re being prescribed for.
What the major societies actually say
The position of mainstream menopause medicine on CBHT has been clear and consistent for more than a decade.
The Menopause Society 2022 Hormone Therapy Position Statement states: “Custom-compounded bioidentical hormone therapy presents safety concerns, such as minimal government regulation and monitoring, overdosing or underdosing, and lack of efficacy and safety data. Custom-compounded hormone therapy is not recommended for the management of menopause symptoms when an FDA-approved formulation is available for an individual’s needs.”
The American College of Obstetricians and Gynecologists (ACOG) has issued Committee Opinion 532, originally published 2012 and reaffirmed: “Evidence is lacking to support superiority claims of compounded bioidentical hormones over conventional menopausal hormone therapy.”
The Endocrine Society Scientific Statement on Bioidentical Hormones concluded that the term “bioidentical hormones” was misleading as commonly used and that compounded products had not been shown to be safer or more effective than FDA-approved hormone therapy.
The FDA has issued public warnings against compounded BHRT marketing claims and has taken enforcement action against compounding pharmacies for unsupported safety and efficacy claims.
This isn’t a fringe medical view. It’s the explicit, repeatedly stated position of every major society that publishes guidelines on menopause care. The reason it doesn’t show up in the consumer-facing internet conversation as often as it should is that the marketing budgets are heavily on one side.
Why CBHT is marketed so aggressively
A reasonable question is why, if mainstream guidelines are uniformly skeptical, CBHT remains widely prescribed and aggressively promoted. The answer is mostly structural and economic.
Compounded products are dispensed and often prescribed by clinicians with direct financial relationships to the compounding pharmacy or to pellet implantation services. Office-based pellet implantation is a cash-pay procedure with substantial markup. Custom compounding is itself a profitable business model. None of this makes individual clinicians dishonest, but it does create incentives that don’t exist around prescribing an FDA-approved patch.
Saliva and “advanced” hormone testing — frequently used to justify custom compounding — is another piece of the model. Salivary hormone levels fluctuate, don’t reliably reflect tissue exposure, and aren’t endorsed by guideline-issuing societies for routine clinical decision-making. But they produce numbers that can be re-tested, adjusted, and billed for, and they generate a sense of personalized precision that FDA-approved standard dosing doesn’t.
The “natural” framing is also powerful. Bioidentical estradiol — whether FDA-approved or compounded — is exactly as “natural” as bioidentical estradiol from a compounder. The molecule is identical. But the marketing of CBHT consistently implies that compounding adds naturalness or personalization that FDA-approved bioidenticals lack, which is not chemically true.
When compounded hormones are actually appropriate
There’s a narrow set of clinical situations in which compounded hormone preparations are reasonable. These are mostly cases where an FDA-approved equivalent does not exist for a specific need:
A patient who needs a hormone preparation in a non-standard delivery system due to an allergy to a component of the FDA-approved version
A patient who requires an unusual dose that no FDA-approved product provides
A patient who cannot use any commercially available formulation due to a specific clinical contraindication
These are the cases The Menopause Society position carves out — compounding “when an FDA-approved formulation is not available for an individual’s needs.” This is a much narrower category than the “personalized hormone therapy” framing suggests, and it doesn’t include most women using CBHT today.
How to think about the choice in your own care
If you’re currently considering bioidentical hormones or have been prescribed compounded BHRT, the practical questions to work through are:
1. What hormones, exactly, are being prescribed?
If estradiol and micronized progesterone, those are available in FDA-approved forms. Ask whether a standard formulation would meet your needs.
2. Is there a clinical reason this can’t be done with FDA-approved products?
In most cases, there isn’t. If you’re being told an FDA-approved option won’t work, ask specifically why.
3. How is the dose being determined?
If the answer involves saliva testing or “advanced” hormone panels rather than your clinical symptoms and standard serum testing where indicated, that’s a flag. Modern hormone therapy is typically titrated to symptom response, with serum testing reserved for specific clinical questions.
4. What does the financial arrangement look like?
If the same clinician who is recommending pellets is implanting them in their office for cash, the structural conflict of interest is worth naming.
5. What’s the evidence base for the specific product you’re being offered?
For FDA-approved estradiol and micronized progesterone, the evidence base includes large randomized trials and decades of clinical experience. For most compounded products, the evidence base is small case series at best.
These aren’t rhetorical questions. They’re the kind of questions a clinician who actually knows the current evidence will welcome, and they’re the kind of questions worth bringing to a visit if you’re trying to decide. Our guide on talking to your doctor about menopause covers how to structure that conversation.
What about saliva and “hormone testing”?
A frequent feature of CBHT marketing is salivary hormone testing or comprehensive serum panels used to identify your “ideal hormone levels.” It’s worth being honest about what these tests can and can’t tell you.
Salivary hormone testing is not validated for clinical decision-making in menopause and is not recommended by The Menopause Society, ACOG, or the Endocrine Society. Salivary levels don’t reliably reflect tissue exposure, fluctuate significantly throughout the day, and don’t correlate well with symptom severity or treatment response.
Serum hormone testing has a narrow role in menopause care. FSH and estradiol can be useful in confirming menopausal status in women under 45 with ambiguous symptoms, evaluating suspected premature ovarian insufficiency (POI), or troubleshooting unexpected treatment failures. Routine serum hormone monitoring to “balance” levels in women on hormone therapy is generally not recommended; treatment is titrated to symptoms.
Comprehensive hormone panels — testosterone, DHEA, pregnenolone, cortisol, full thyroid panels, etc. — produce a lot of numbers, but most of those numbers don’t have established clinical decision thresholds in the menopause context. The Menopause Society, ACOG, and the Endocrine Society have all explicitly cautioned against using these panels as a basis for compounded hormone prescribing.
This isn’t to say testing has no place. It is to say that the volume of numbers produced by aggressive panel testing tends to exceed the clinical decisions those numbers can actually support, and that “we balanced your hormones to your individual levels” is a marketing line, not a treatment paradigm with evidence behind it.
What this means for you
A practical synthesis for women trying to make a decision:
If you want bioidentical hormone therapy, you can get it through FDA-approved products. Transdermal estradiol plus oral micronized progesterone is bioidentical, well-studied, FDA-approved, regulated, and supported by every major menopause society. This is the modern standard of care for women with moderate-to-severe symptoms and no contraindications.
If you’ve been told compounded BHRT is safer or more natural than FDA-approved bioidenticals, that claim is not supported by the evidence base or by guideline-issuing societies. Both contain bioidentical hormones. One is regulated, dose-standardized, and studied. The other is not.
If you’re currently on compounded BHRT and it’s working for you without adverse effects, you may not need to change anything immediately. But the relevant question is whether the same outcome could be achieved with FDA-approved products with better regulatory protection and a stronger evidence base, and whether the testing being done to monitor your therapy is actually clinically meaningful.
Pellet implantation specifically warrants caution. Supratherapeutic hormone levels from pellets can produce significant side effects that persist for months because the pellets can’t easily be removed once implanted. Several state medical boards have issued advisories about pellet-related complications. If pellets are being recommended, ask why an adjustable formulation (patch, gel, oral) isn’t being offered instead.
Saliva testing is not a reliable basis for hormone dosing. If you’re being asked to retest saliva levels every few months to “adjust your formulation,” the underlying testing strategy isn’t supported by the evidence.
For more on the comparative risk-benefit picture of hormone therapy as a whole, our pillars on HRT explained, HRT benefits, and is HRT safe cover the broader context.
When to talk to your doctor
Reasonable triggers for a clinical conversation include:
You’ve been prescribed compounded BHRT and want to understand whether an FDA-approved equivalent would meet your needs
You’re being offered pellet implantation and want to understand the alternatives
Your hormone therapy is being adjusted based on saliva or “advanced” hormone testing and you want to understand whether those tests are guiding clinically meaningful decisions
You’re considering hormone therapy for the first time and want to understand the difference between the products being marketed to you
You’ve experienced side effects on compounded BHRT and aren’t sure whether to switch formulations or stop
Look for a clinician who is willing to discuss the evidence behind specific products and who isn’t structurally invested in dispensing the medication they’re recommending. The Menopause Society maintains a directory of certified menopause practitioners that can be a useful starting point.
Frequently asked questions
Are bioidentical hormones safer than traditional HRT?
Not categorically. The molecule itself is identical when you compare FDA-approved estradiol or micronized progesterone to compounded versions. What changes is the regulatory standard, the dosing consistency, and the evidence base. FDA-approved bioidentical hormones are the safest evidence-supported option. Compounded bioidentical hormones have not been shown to be safer than FDA-approved hormone therapy and are not recommended by the major societies when an FDA-approved option exists.
Is estradiol the same as “bioidentical estrogen”?
Yes. 17-beta estradiol is the bioidentical form of estrogen — the same molecule your ovaries produced during your reproductive years. FDA-approved estradiol patches, gels, sprays, oral tablets, and vaginal preparations all contain bioidentical estradiol.
What about progesterone — is it the same as bioidentical progesterone?
Yes. Oral micronized progesterone (Prometrium and generics) is bioidentical and FDA-approved. It is the standard progestogen used alongside estradiol in modern menopause hormone therapy for women with a uterus. It is distinct from medroxyprogesterone acetate (MPA, Provera), which is a synthetic progestin used in some older HT regimens.
Why do some clinicians prescribe pellets if they’re not recommended by guidelines?
A combination of marketing, financial incentives associated with the procedure, and the patient demand created by both. Some patients also report subjective benefits on pellets that they didn’t get from other formulations, though this isn’t supported by controlled trials. The clinical concerns — supratherapeutic levels, irreversibility, lack of dosing standardization — are why the major societies have cautioned against routine use.
Should I get a saliva hormone test?
Probably not, if the goal is guiding menopause hormone therapy decisions. Salivary hormone testing isn’t validated for that purpose and isn’t recommended by The Menopause Society, ACOG, or the Endocrine Society. Modern hormone therapy is titrated to symptoms, with serum testing reserved for specific clinical questions.
Is there ever a reason to choose compounded over FDA-approved hormones?
Yes — but the situations are narrow. Allergies to inactive ingredients in FDA-approved products, the rare need for a non-standard dose, or specific clinical contexts where no FDA-approved equivalent exists. These cases are uncommon and don’t apply to most women using CBHT today.
Sources
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
American College of Obstetricians and Gynecologists. Committee Opinion No. 532: Compounded Bioidentical Menopausal Hormone Therapy. Obstetrics and Gynecology. 2012;120(2 Pt 1):411-415. Reaffirmed 2020.
Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. Journal of Clinical Endocrinology and Metabolism. 2010;95(7 Suppl 1):s1-s66.
Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment. 2008;107(1):103-111.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative. JAMA. 2002;288(3):321-333.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318(10):927-938.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
The Menopause Society. Menopause Practitioner Directory.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Hormone therapy, whether FDA-approved or compounded, requires evaluation by a clinician familiar with menopause medicine. Contraindications include estrogen-sensitive cancer history, active venous thromboembolism, active liver disease, and unexplained vaginal bleeding, among others. This article describes the regulatory and evidence landscape and does not constitute a recommendation for or against any specific product for any specific patient.
